TITLE

COMMENTARY: Review: Pioglitazone does not reduce risk for mortality or cardivascular events in type 2 diabetes

AUTHOR(S)
Smith, Donald
PUB. DATE
March 2007
SOURCE
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's views about a study which states that pioglitazone does not reduce risk for mortality or cardivascular events in type 2 diabetes. The study lasted for 35 months and included patients with diabetes and macrovascular disease at baseline. Pioglitazone did not lower the risk for the primary endpoints, it did result in a statistically significant 2% absolute risk reduction in a secondary composite endpoint of myocardial infarction.
ACCESSION #
24685674

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics